These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 14769135)

  • 1. Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.
    Laterra JJ; Grossman SA; Carson KA; Lesser GJ; Hochberg FH; Gilbert MR;
    Neuro Oncol; 2004 Jan; 6(1):15-20. PubMed ID: 14769135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.
    Mikkelsen T; Lush R; Grossman SA; Carson KA; Fisher JD; Alavi JB; Rosenfeld S
    Invest New Drugs; 2007 Jun; 25(3):259-63. PubMed ID: 17080256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
    Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
    J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.
    Grossman SA; Ye X; Chamberlain M; Mikkelsen T; Batchelor T; Desideri S; Piantadosi S; Fisher J; Fine HA
    J Clin Oncol; 2009 Sep; 27(25):4155-61. PubMed ID: 19636006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme.
    Ballman KV; Buckner JC; Brown PD; Giannini C; Flynn PJ; LaPlant BR; Jaeckle KA
    Neuro Oncol; 2007 Jan; 9(1):29-38. PubMed ID: 17108063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
    Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
    Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
    Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
    Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
    Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
    Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
    J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.
    Minniti G; Armosini V; Salvati M; Lanzetta G; Caporello P; Mei M; Osti MF; Maurizi RE
    J Neurooncol; 2011 Jul; 103(3):683-91. PubMed ID: 21052773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in glioblastoma multiforme patients receiving high-dose particle radiotherapy or conventional radiotherapy.
    Matsuda M; Yamamoto T; Ishikawa E; Nakai K; Zaboronok A; Takano S; Matsumura A
    Br J Radiol; 2011 Dec; 84 Spec No 1(Spec Iss 1):S54-60. PubMed ID: 21427185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
    Grossman SA; Ye X; Piantadosi S; Desideri S; Nabors LB; Rosenfeld M; Fisher J;
    Clin Cancer Res; 2010 Apr; 16(8):2443-9. PubMed ID: 20371685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
    Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
    World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme.
    Athanassiou H; Synodinou M; Maragoudakis E; Paraskevaidis M; Verigos C; Misailidou D; Antonadou D; Saris G; Beroukas K; Karageorgis P
    J Clin Oncol; 2005 Apr; 23(10):2372-7. PubMed ID: 15800329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
    Chang EL; Loeffler JS; Riese NE; Wen PY; Alexander E; Black PM; Coleman CN
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):65-70. PubMed ID: 9422559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
    Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
    Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
    Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice.
    Carter TC; Medina-Flores R; Lawler BE
    Biomed Res Int; 2018; 2018():6204676. PubMed ID: 30687753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.
    Fabi A; Mirri A; Felici A; Vidiri A; Pace A; Occhipinti E; Cognetti F; Arcangeli G; Iandolo B; Carosi MA; Metro G; Carapella CM
    J Neurooncol; 2008 Mar; 87(1):79-84. PubMed ID: 17987263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
    Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
    J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.